within Pharmacolibrary.Drugs.ATC.N;

model N06AA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.32,
    Cl             = 76 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.0114,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Opipramol is a tricyclic antidepressant primarily used for its anxiolytic and antidepressant effects, approved for the treatment of generalized anxiety disorder and somatoform disorders but not for major depressive disorder. It remains in clinical use, particularly in some European countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Kanarkowski, R, &amp; Wichliński, LM (1985). Correlation between the rate of dissolution and absorption of opipramol from solid oral forms. <i>Materia medica Polona. Polish journal of medicine and pharmacy</i> 17(2) 85–87. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4079473/&quot;>https://pubmed.ncbi.nlm.nih.gov/4079473</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AA05;
